vaccin
vaccin
vector
term
genet
modifi
gm
recombin
gene
technolog
use
creat
vaccin
vector
genet
modifi
virus
gmv
viru
vector
homolog
heterolog
diseas
antigen
consid
highli
desir
vaccin
diseas
difficult
treat
exist
effect
convent
vaccin
eg
acquir
immun
defici
syndrom
aid
malaria
tuberculosi
neoplast
disord
advantag
gmv
vaccin
enhanc
immunogen
without
adjuv
induct
robust
cytotox
lymphocyt
respons
elimin
virusinfect
cell
mani
virus
use
gmv
vaccin
purpos
major
one
poxvirida
vaccinia
viru
vacv
retrovirida
includ
lentiviru
adenovirida
human
adenoviru
hadv
parvovirida
adenoassoci
viru
aav
herpesvirida
cytomegaloviru
cmv
paramyxovirida
sendai
viru
sev
uniqu
attribut
associ
risk
use
gm
viru
vaccin
vector
vacvbas
vector
good
histor
preced
safeti
vacv
modifi
vaccinia
viru
ankara
mva
use
smallpox
vaccin
vacvbas
vector
also
well
toler
clinic
trial
although
advers
effect
record
studi
high
dose
pfu
mva
disadvantag
vector
base
vacv
includ
limit
immunogen
preexist
immun
recombin
adv
vector
advantag
high
transduct
effici
high
level
transgen
express
broad
cell
tropism
abil
infect
divid
nondivid
cell
adv
vector
also
well
toler
presenc
preexist
antiadv
immun
disadvantag
associ
similar
adv
aav
infect
divid
nondivid
cell
broad
cell
tropism
addit
aav
vector
also
provid
longterm
transgen
express
howev
may
requir
host
genom
integr
viral
gene
express
retroviru
aav
vector
provid
longterm
gene
express
plagu
preexist
immun
howev
packag
size
limit
kilobas
respect
retrovirus
associ
variou
diseas
eg
leukemia
lymphoma
aid
vector
deriv
sev
show
high
effici
gene
transfer
transduc
divid
nondivid
cell
sev
infect
human
epitheli
cell
effici
therefor
administ
intranas
reduc
influenc
preexist
immun
compar
intramuscular
administr
advantagesbenefit
variou
gmv
exploit
improv
virusbas
gm
vaccin
effort
underway
reduc
limit
environment
risk
assess
era
govern
regulatori
instrument
differ
countri
region
european
union
eu
era
govern
direct
contain
guidelin
step
annex
part
iv
direct
direct
stipul
stepwis
casebycas
process
hazard
identifi
character
exposur
pathway
evalu
potenti
risk
character
routin
era
procedur
base
direct
involv
follow
step
hazard
identif
hazard
character
assess
likelihood
hazard
risk
level
risk
character
risk
manag
strategi
determin
overal
risk
conclus
aim
era
assess
risk
human
environ
product
deriv
genet
modif
proffer
manag
mitig
strategi
environment
risk
associ
gmv
wide
publish
gener
hazard
potenti
risk
environ
gmv
link
shed
surviv
natur
toxic
transgen
dissemin
transfer
novelforeign
gene
wildtyp
virus
well
contact
infect
nontarget
individu
anim
environ
poxvirus
linear
doubl
strand
dna
genom
approxim
kbp
seal
parapox
viru
kbp
canarypox
viru
entir
morphogenesi
within
cytoplasm
infect
cell
mileston
vaccinolog
achiev
smallpox
highli
lethal
diseas
caus
variola
viru
varv
member
genu
orthopoxviru
famili
poxvirida
offici
declar
extinct
variola
major
minor
virus
account
approxim
mortal
smallpox
believ
emerg
around
bc
origin
varv
unknown
protect
smallpox
achiev
transfer
materi
scab
taken
smallpox
patient
uninfect
individu
variol
call
result
case
fatal
rate
nevertheless
introduc
europ
centuri
edward
jenner
introduc
principl
vaccin
demonstr
cowpox
viru
cpxv
could
use
prevent
smallpox
infect
quickli
gain
accept
initi
vaccin
perform
cpxv
later
vacv
becam
vaccin
strain
choic
origin
vacv
remain
unknown
shroud
mysteri
controversi
smallpox
estim
respons
million
death
worldwid
centuri
alon
world
health
organ
launch
strateg
plan
elimin
smallpox
smallpox
announc
erad
assembl
may
success
erad
smallpox
possibl
due
earli
recognit
diagnosi
diseas
quarantin
patient
effect
vaccin
fact
varv
infect
human
anim
host
reservoir
discoveri
vacv
use
vector
express
heterolog
transgen
mammalian
cell
potenti
varv
deploy
agent
bioterror
increas
zoonot
potenti
mani
orthopoxvirus
opv
especi
vacv
cpxv
monkeypox
viru
mpxv
lead
resurg
poxviru
research
especi
vaccin
develop
erad
smallpox
recombin
vaccin
base
poxviru
good
candid
prophylact
therapeut
vaccin
human
anim
infecti
diseas
neoplasm
poxvirus
suitabl
vaccin
vector
thermost
infect
differ
host
cell
type
multipli
cytoplasm
infect
cell
capac
insert
express
kbp
foreign
dna
well
eas
scalabl
commerci
product
among
opvvector
vaccin
rabor
vrg
rvg
recombin
rabi
vaccin
base
vacv
regist
rgv
use
vaccin
rabi
raccoon
fox
north
america
europ
except
oncolyt
agent
multipl
compet
poxviru
vaccin
recommend
vaccin
particularli
human
due
risk
advers
effect
multipl
incompet
poxviru
vector
develop
safer
altern
multipl
compet
vector
includ
mva
attenu
vacv
copenhagen
nyvac
attenu
deriv
fowlpox
viru
trovac
canarypox
viru
alvac
multipl
defici
poxviru
vector
form
backbon
poxvirusvector
vaccin
preclin
develop
clinic
trial
market
author
applic
maa
evalu
mva
arguabl
promis
viru
vector
due
capac
express
wide
array
transgen
correct
posttransl
modif
immunogen
vivo
along
safeti
profil
includ
host
restrict
mammalian
cell
attenu
vivo
domest
intern
legisl
requir
era
virusvector
vaccin
submit
evalu
part
maa
clinic
trial
applic
particular
interest
era
characterist
mva
vector
interact
host
environ
may
result
immedi
delay
risk
human
anim
health
well
environ
strong
safeti
profil
mvavector
vaccin
well
histori
safe
use
smallpox
vaccin
stagnat
research
aspect
biolog
vector
still
poorli
understood
also
relev
optim
safeti
mva
thu
underli
assumpt
mva
safe
studi
aim
risk
character
vector
either
regard
irrelev
unequivoc
address
scientif
literatur
hazard
character
era
step
mva
mvavector
vaccin
would
requir
knowledg
natur
distribut
natur
circul
opv
may
rescu
mva
coinfect
superinfect
ii
recombin
mvavector
vaccin
natur
occur
opv
coinfectionsuperinfect
cell
cultur
immunecompet
immunecompromis
anim
iii
mva
host
restrict
human
cell
molecular
basi
restrict
iv
clonal
puriti
mva
stock
v
genom
transgen
stabil
mva
mvavector
vaccin
follow
multipl
serial
passag
vi
viru
host
factor
modul
transgen
stabil
vii
effect
express
transgen
virushost
transcriptom
proteom
metabolom
epigenom
viii
biodistribut
shed
immunecompet
immunecompromis
individu
aim
review
identifi
gap
knowledg
respect
hazard
character
mva
vectormvavector
vaccin
highlight
ongo
futur
experi
aim
address
knowledg
gap
contribut
robust
era
mva
vectormvavector
vaccin
optim
mva
safe
vaccin
vector
differ
variant
vacv
use
vaccin
smallpox
mva
origin
gener
serial
passag
chorioallantoi
vaccinia
viru
ankara
cva
chicken
embryo
fibroblast
cell
cef
produc
bavarian
state
vaccin
institut
germani
use
human
smallpox
vaccin
serial
passag
time
viru
cef
cultur
result
major
delet
mutat
viral
genom
loss
approxim
kbp
modif
also
affect
virul
immun
evas
function
result
highli
attenu
vaccin
viru
produc
low
degre
advers
effect
vaccine
complet
replic
cycl
mva
restrict
avian
cell
human
mammalian
cell
viru
replic
dna
unimpair
express
earli
intermedi
gene
well
late
gene
block
stage
virion
assembl
thu
produc
infecti
progeni
howev
mva
still
abl
express
viral
gene
includ
insert
gene
ie
encod
antigen
vaccin
direct
thu
stimul
immun
system
recipi
relev
way
mva
vaccin
smallpox
administ
mostli
intraderm
subcutan
often
use
germani
first
vaccin
usual
vacciniana
children
adult
could
risk
advers
effect
vaccin
less
attenu
smallpox
vaccin
mva
vaccin
elicit
weak
viru
neutral
antibodi
respons
first
prime
immun
system
follow
vacv
smallpox
vaccin
result
effect
immun
respons
protect
smallpox
howev
later
discov
weak
neutral
antibodi
elicit
mva
prime
hemagglutinin
ha
protein
vacv
antibodi
neutral
assay
base
absent
mva
due
truncat
ha
promot
respons
mva
vaccine
experienc
mild
local
reaction
redden
vaccin
inocul
site
develop
blister
pustul
ulcer
vaccine
develop
fever
ie
develop
nonspecif
gener
symptom
mva
vaccin
licens
germani
administ
person
howev
vaccin
conduct
smallpox
longer
endem
germani
thu
immunolog
efficaci
fulli
virul
varv
remain
unknown
proven
protect
primat
lethal
monkeypox
infect
develop
optim
mva
smallpox
vaccin
continu
post
smallpox
erad
part
driven
concern
smallpox
viru
may
reemerg
either
due
accident
escap
contain
due
bioterror
henc
public
health
need
optim
mva
effect
safer
altern
multipl
compet
smallpox
vaccin
european
medicin
agenc
ema
regist
mvabn
smallpox
vaccin
mvabn
singl
clone
deriv
follow
six
round
plaqu
purif
current
mvabn
host
restrict
mva
variant
vitro
well
attenu
vivo
mva
develop
cva
passag
cef
result
loss
approxim
kbp
parent
cva
genom
sever
gene
code
host
rang
factor
immunomodul
either
lost
fragment
mva
highli
host
restrict
undergo
abort
infect
human
mammalian
cell
test
far
except
babi
hamster
kidney
cell
rat
small
intestin
epitheli
cell
cell
line
deriv
egyptian
fruit
bat
howev
signific
variabl
suscept
mva
strain
mammalian
cell
line
tabl
product
infect
human
cell
line
mvabn
undergo
abort
infect
mammalian
cell
line
tabl
even
nonpermiss
cell
determin
fold
increas
viru
titer
limit
product
matur
mva
virion
attenu
mva
vivo
depend
strain
variant
mva
strain
produc
abort
infect
intact
anim
host
shown
nonpathogen
even
immunedefici
anim
human
although
variant
virul
immunedefici
mice
compar
multipl
compet
vacv
mva
induc
rapid
immun
respons
activ
innat
immun
system
follow
discoveri
vacv
express
heterolog
gene
effici
mammalian
cell
mva
undergon
rapid
develop
viru
vector
vaccin
infecti
diseas
cancer
uniqu
characterist
nonproduct
infect
human
cell
attenu
vivo
gener
rapid
immun
respons
robust
activ
innat
immun
system
posit
mva
viru
vector
choic
although
vaccin
licens
human
use
sever
mvavector
vaccin
hivaid
tuberculosi
malaria
ebola
influenza
hepat
b
alreadi
clinic
trial
sever
candid
vaccin
plethora
human
diseas
preclin
trial
apart
human
infecti
diseas
recombin
mva
vaccin
cancer
preclin
clinic
develop
mva
also
attract
effici
viru
vector
develop
recombin
vaccin
diseas
domest
anim
wildlif
although
mva
shown
great
promis
vector
recombin
vaccin
still
need
improv
efficaci
safeti
mva
optim
improv
vaccin
efficaci
delet
intact
vacv
immunomodulatori
gene
insert
gene
encod
costimulatori
molecul
precis
regul
gene
express
endogen
synthet
promot
contrari
studi
aim
attenu
mva
vector
miniscul
probabl
due
assumpt
develop
mva
reach
satisfactori
level
safeti
addit
attenu
may
compromis
immunogen
mva
vector
gener
believ
pose
low
neglig
risk
human
anim
environ
claim
overwhelm
indisput
scientif
evid
support
assert
howev
scientif
consensu
undermin
research
biosafeti
risk
character
mva
vector
omit
priorit
remain
unpublish
number
peer
review
articl
publish
two
arm
mva
vaccin
research
efficaci
immunogen
ii
biosafeti
environment
risk
assess
chosen
indic
research
prioriti
object
pubm
search
modifi
vaccinia
viru
ankara
keyword
append
object
prefix
suffix
prefix
suffix
object
search
independ
number
publish
articl
record
pubm
search
conduct
juli
queri
object
modifi
vaccinia
viru
ankara
modifi
vaccinia
viru
ankara
vaccin
articl
respect
retriev
keyword
deal
efficaci
immunogen
mva
return
higher
number
publish
articl
wherea
keyword
deal
biosafeti
era
return
hit
databas
queri
keyword
mva
safeti
instead
mva
biosafeti
number
articl
increas
howev
safeti
studi
biosafeti
environment
risk
studi
often
misconstru
safeti
studi
deal
potenti
advers
effect
patient
direct
recipi
mva
vaccin
wherea
era
studi
deal
evalu
potenti
advers
effect
environ
outsid
patient
sinc
gener
keyword
deal
era
biosafeti
gener
hit
expand
search
use
sever
specif
keyword
like
mva
offtarget
effect
mva
genom
stabil
mva
shed
mva
biodistribut
other
return
low
number
publish
articl
except
modifi
vaccinia
viru
ankara
recombin
return
hit
howev
except
three
articl
deal
recombin
risk
assess
context
remaind
deal
construct
recombin
mva
pubm
search
demonstr
enorm
data
pool
immunogen
mva
littl
peerreview
data
biosafeti
era
inabl
mva
undergo
product
infect
human
cell
mammalian
origin
main
reason
mva
regard
safe
viru
vector
approv
licens
smallpox
vaccin
within
eu
ema
committe
medicin
product
human
use
chmp
state
regard
safeti
vaccinia
viru
imvanex
replic
human
cell
henc
less
like
caus
side
effect
previou
smallpox
vaccin
imvanex
would
therefor
benefici
peopl
given
vaccin
contain
replic
virus
patient
weaken
immun
system
molecular
basi
nonproduct
infect
human
mammalian
cell
mva
remain
unknown
thu
creat
major
knowledg
gap
hazard
character
mva
molecular
determin
host
restrict
identifi
certainti
mva
multipli
effici
human
cell
earlier
suggest
absenc
host
rang
gene
presenc
six
major
delet
mva
genom
may
respons
sever
host
cell
defect
shown
incorrect
replic
compet
vacv
host
rang
gene
still
intact
mva
ii
marker
rescu
nonfunct
host
rang
gene
kil
function
copi
restor
host
cell
tropism
wildtyp
cva
iii
marker
rescu
larg
fragment
cva
genom
restor
wildtyp
phenotyp
iv
importantli
sequenti
introduct
six
major
delet
cva
genom
recreat
mva
host
restrict
phenotyp
thu
six
major
delet
absenc
two
vacv
host
rang
gene
essenti
sever
host
rang
defect
mva
research
identifi
molecular
determin
mva
host
cell
defect
human
mammalian
cell
stagnat
presum
beliefassumpt
mva
undergo
product
infect
human
cell
present
role
insertionsdelet
indel
singl
nucleotid
polymorph
snp
mva
nonproduct
infect
human
cell
either
singli
combin
six
major
delet
remain
uninvestig
also
attempt
readapt
mva
multipli
human
cell
way
understand
viru
host
cell
determin
host
cell
tropism
sinc
mva
host
cell
restrict
human
mammalian
cell
achiev
multipl
serial
passag
cef
hypothes
mva
readapt
multipli
human
cell
multipl
serial
passag
human
cell
line
infect
nonpermiss
human
atcc
cell
mva
atcc
low
multipl
infect
moi
blindli
passag
time
abl
show
log
fold
increas
viru
titer
figur
product
matur
virion
figur
abl
isol
plaqu
purifi
mva
variant
abl
undergo
effici
product
infect
cell
observ
demonstr
least
cell
host
defect
mva
may
revers
altern
may
indic
spite
passag
extens
plaqu
purif
variant
capabl
product
infect
still
present
within
mva
vaccin
stock
atcc
current
investig
product
infect
potenti
mva
variant
human
cell
line
primari
human
cell
well
sequenc
genom
compar
nonpassag
mva
atcc
vr
futur
work
extend
experi
mvabn
examin
attenuationvirul
potenti
product
mva
variant
immunocompet
immunocompromis
vivo
infect
model
result
studi
shed
light
host
restrict
defect
mva
human
cell
relev
era
mva
vector
result
vitro
studi
replic
vivo
robust
hazard
character
viru
vector
demonstr
vector
clonal
pure
genet
stabl
passag
level
titer
equival
present
product
batch
mva
vector
assum
homogen
follow
passag
cef
subsequ
three
round
plaqu
purif
ident
genom
sequenc
independ
mva
strain
least
five
independ
laboratori
present
evid
mva
clonal
puriti
genom
stabil
howev
next
gener
sequenc
approach
use
sequenc
genom
report
genom
predomin
mva
clone
variant
sinc
design
determin
minor
variant
present
demonstr
clonal
puriti
mva
requir
deep
sequenc
stock
master
seed
viru
msv
tandem
sequenc
sever
mva
clone
obtain
stock
follow
least
three
round
plaqu
purif
vaccin
shown
polyclon
use
genom
wide
sequenc
design
examin
variant
present
isol
genom
wide
map
variant
within
mva
stock
msv
never
report
one
studi
employ
passag
mva
strain
immunedefici
mice
shown
examin
mva
strain
except
mvabn
polyclon
howev
observ
studi
show
mvabn
homogen
confirm
mvabn
subject
deep
sequenc
combin
genom
sequenc
independ
clone
isol
mvabn
sinc
mva
subject
select
pressur
multipl
multipl
cycl
product
high
titer
viru
stock
intend
vaccin
essenti
examin
genom
stabil
viru
across
msv
msv
human
cell
line
immunecompet
immunecompromis
anim
model
present
inform
provid
era
dossier
submit
clinic
trial
maa
relev
eu
direct
direct
made
provis
data
obligatori
data
evolut
mva
permiss
cell
good
manufactur
practic
gmp
manufactur
enabl
risk
assessor
evalu
genom
stabil
mva
presenc
variant
product
batch
intend
vaccin
emerg
quasispeci
role
modul
mva
phenotyp
includ
host
rang
infect
attenu
virul
biodistribut
omit
research
field
need
address
order
reach
scale
requir
current
gmp
mvavector
vaccin
intend
clinic
applic
vaccin
need
amplifi
multipl
time
high
titer
amplif
creat
select
pressur
may
result
instabl
recombin
mva
instabl
may
occur
within
transgen
express
cassett
transgen
instabl
outsid
express
cassett
genom
instabl
provis
genom
sequenc
msv
five
passag
necessari
order
evalu
genom
stabil
recombin
vaccin
base
mva
howev
provis
whole
genom
sequenc
mandatori
direct
thu
genom
stabil
mvavector
vaccin
intend
clinic
applic
remain
unknown
potenti
mutat
outsid
express
cassett
phenotyp
implic
mutat
go
unreport
transgen
stabil
recombin
mvavector
vaccin
routin
examin
hazard
character
group
report
influenza
viru
hemagglutinin
ha
transgen
cpxvmva
recombin
unstabl
result
loss
transgen
follow
serial
passag
southern
blot
analysi
suggest
ha
transgen
first
recombin
mvavector
vaccin
unstabl
group
also
report
transgen
instabl
mvavector
vaccin
transgen
stabil
essenti
robust
era
sinc
transgen
logic
tag
track
spread
vaccin
viru
target
recipi
nontarget
speci
consequ
loss
transgen
may
preclud
monitor
nontarget
effect
releas
escap
recombin
mva
vaccin
studi
viral
host
factor
modul
transgen
stabil
miniscul
except
effect
transgen
insert
site
promot
choic
promot
spacer
length
express
level
transgen
time
transgen
express
sequencestructur
transgeneflank
region
host
cell
use
viru
amplif
transgen
stabil
poorli
understood
elucid
viru
host
determin
transgen
instabl
essenti
knowledg
deploy
design
transgen
mva
vaccin
probabl
transgen
instabl
extrem
low
neglig
studi
transgen
stabil
done
establish
cell
line
knowledg
report
transgen
instabl
underli
mechan
investig
vivo
particularli
relev
immunocompromis
infect
model
immunocompromis
human
domest
anim
wildlif
popul
subset
may
expos
recombin
mva
vaccin
thu
stabil
transgen
immunocompromis
anim
model
investig
data
obtain
guid
era
recombin
mva
interact
virusvector
vaccin
natur
circul
wildtyp
virus
essenti
era
sinc
baselin
data
occurr
natur
geograph
distribut
later
requir
order
evalu
potenti
recombin
complement
reactiv
revers
wildtyp
viru
case
mva
requir
knowledg
occurr
distribut
characterist
natur
circul
opv
locat
ecosystem
recombin
mva
vaccin
deploy
especi
vaccin
domest
anim
wildlif
except
germani
unit
kingdom
fennoscandia
usa
brazil
india
data
occurr
characterist
wildtyp
opv
remain
region
globe
limit
nonexist
mvavector
vaccin
malaria
hivaid
tuberculosi
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
sever
human
anim
diseas
trial
africa
asia
middl
east
knowledg
characterist
reservoir
anim
speci
wildtyp
opv
region
larg
nonexist
consequ
scientif
valid
infer
made
potenti
virusviru
interact
recombin
mva
vaccin
natur
occur
viru
rel
region
even
recombin
poxviru
vaccin
releas
area
knowledg
exist
characterist
occurr
natur
circul
rel
systemat
studi
undertaken
post
releas
monitor
occurr
potenti
advers
effect
due
interact
genet
modifi
poxviru
vaccin
natur
circul
opv
raboralvrg
vacvvector
rabi
vaccin
alongsid
attenu
rabi
viru
vaccin
success
use
region
belgium
franc
erad
fox
rabi
western
part
europ
campaign
start
three
decad
ago
surveil
program
monitor
efficaci
vaccin
ie
preval
rabi
ongo
report
exist
interact
vrg
natur
circul
opv
fox
wildlif
europ
comprehens
genom
wide
map
opv
fox
anim
fox
food
chain
region
raboralvrg
bait
vaccin
use
would
yield
data
would
help
risk
assessor
evalu
potenti
recombin
complement
revers
vector
back
wild
type
thu
absenc
data
natur
circul
opv
releas
recombin
poxviru
includ
mva
vector
vaccin
signific
knowledg
gap
era
mvavector
vaccin
recombin
poxvirusvector
vaccin
natur
circul
opv
coinfect
superinfect
cellshost
signific
term
era
recombin
potenti
restor
product
infect
multiplicationincompet
vaccinevector
well
gener
hybrid
virus
alter
host
rang
cell
tropism
transmiss
virul
although
recombin
known
occur
among
replic
poxvirus
inde
method
construct
recombin
poxvirusvector
vaccin
studi
aim
investig
recombin
mvavector
vaccin
opv
rare
previous
demonstr
recombin
occur
mvavector
influenza
vaccin
natur
circul
cpxv
coinfect
cell
gener
progeni
hybrid
virus
parent
nonparent
characterist
provis
data
potenti
recombin
mvavector
vaccin
wildtyp
opv
obligatori
direct
may
explain
pauciti
data
issu
present
era
mvavector
vaccin
evalu
potenti
recombin
recombin
mva
vaccin
natur
circul
opv
risk
recombin
said
neglig
recombin
recombin
mva
vaccin
wild
type
opv
deem
unlik
mva
produc
infecti
virion
human
cell
mammalian
origin
well
due
repuls
superinfect
virion
howev
abort
infect
repuls
superinfect
virion
suffici
prevent
recombin
sinc
recombin
requir
presenc
homolog
dna
repuls
infecti
virion
absolut
leaki
although
opv
infect
shortliv
dnaemia
last
four
week
report
cpxv
time
window
recombin
occur
mva
recombin
mva
use
vaccin
host
sinc
dna
replic
impair
mva
nonproduct
infect
semi
nonpermiss
cell
recombin
mva
wildtyp
opv
coinfect
superinfect
exclud
examin
potenti
recombin
cell
mva
multipli
poorli
vero
cell
coinfect
mvavector
influenza
vaccin
mvahanp
felin
cpxv
fcpxv
infect
mvahanp
fcpxv
respect
thereaft
superinfect
either
fcpxv
mvahanp
variou
time
post
primari
viru
infect
ppi
result
show
recombin
occur
visual
plaqu
coinfect
cell
plaqu
superinfect
cell
express
transgen
figur
transgen
express
mvafcpxv
recombin
progeni
figur
nontransgen
express
mvafcpxv
recombin
display
differ
plaqu
phenotyp
result
demonstr
recombin
mva
vaccin
recombin
natur
circul
opv
coinfect
superinfect
mammalian
cell
semipermiss
mva
ii
repuls
superinfect
virion
prevent
recombin
recombin
mva
wildtyp
opv
present
extend
experi
nonpermiss
cell
immunecompet
immunedefici
anim
model
well
map
genomewid
pattern
recombin
alreadi
isol
recombin
result
cell
cultur
replic
intact
anim
model
potenti
recombin
examin
mvavector
vaccin
maa
clinic
trial
applic
sought
addit
present
emphasi
likelihood
frequenc
occurr
consequ
need
reexamin
consider
also
given
impact
consequ
presum
rare
event
like
recombin
rare
recombin
event
may
gener
progeni
hybrid
virus
virul
parent
strain
natur
occur
opv
like
cpxv
mpxv
vacv
may
becom
virul
acquir
transgen
encod
costimulatori
molecul
mvavector
vaccin
follow
unlik
recombin
event
among
alphaherpesvirus
recombin
attenu
infecti
laryngotrach
viru
vaccin
strain
result
emerg
virul
field
isol
virusvectortransgen
potenti
dispers
throughout
bodi
administ
via
rout
alimentari
canal
potenti
transmiss
sex
cell
attend
risk
transmiss
offspr
mva
reach
target
tissu
site
administr
howev
multipl
incompet
mva
rapidli
clear
tissu
situat
genet
modif
alter
tissu
tropism
gmv
biodistribut
affect
especi
multipl
compet
gmv
result
infect
cell
natur
permiss
origin
parent
viru
inform
relev
map
dissemin
recombin
vector
biodistribut
may
also
influenc
time
window
rout
shed
viru
recipi
thu
likelihood
transmiss
third
parti
includ
vertic
transmiss
transmiss
vectorrecombin
vaccin
individu
host
speci
import
map
biodistribut
virusvectorrecombin
vaccin
immunecompromis
individu
given
biodistribut
immunecompromis
expect
differ
immunecompet
individu
provid
valuabl
data
recombin
vaccin
may
affect
impair
immun
system
environ
expos
viru
vectorvirusvector
vaccin
shed
vaccin
recipi
case
hospit
personnel
caregiv
nonvacine
other
may
expos
especi
viru
vector
shed
via
bodi
fluid
evalu
shed
biolog
properti
viru
vectorvirusvector
vaccin
biodistribut
statu
host
includ
immunocompet
dose
rout
administr
sampl
frequenc
durat
sampl
method
sampl
analysi
data
interpret
import
consider
addit
inform
biolog
properti
wildtyp
strain
provid
guidanc
shed
evalu
similar
biodistribut
multipl
compet
viru
vector
import
consider
evalu
shed
given
multipl
compet
viru
vector
may
persist
vaccine
extend
period
time
increas
amount
lead
higher
shed
infecti
particl
associ
likelihood
viru
transmiss
multipl
compet
viru
vector
import
analyz
molecular
variant
also
influenc
viru
shed
gener
basic
assumpt
era
multipl
compet
viru
vector
likelihood
spread
viral
vector
vaccine
environ
immun
statu
recipi
affect
shed
hazard
becom
higher
multipl
compet
viru
vector
case
evalu
viru
vector
multipl
incompet
shed
viru
unlik
evid
provid
case
protein
encod
insert
transgen
alter
multipl
incompet
vector
abil
viru
vector
surviv
shed
vaccine
well
stabil
insert
genet
materi
environ
influenc
chanc
nonvaccin
organ
expos
persist
commonli
use
viral
vector
genet
modifi
gm
vaccin
gene
therapi
discuss
baldo
et
al
although
poxvirus
show
high
environment
stabil
resist
dri
may
remain
contagi
period
sever
month
ambient
temperatur
nevertheless
sensit
easili
inactiv
disinfect
commonli
approv
surfac
disinfect
persist
viral
particl
dna
environ
affect
sever
factor
review
includ
presenc
absenc
proteolyt
microorgan
lipid
protein
materi
serv
protect
shield
viru
particl
ph
temperatur
freezethaw
cycl
presenc
absenc
dnase
ph
length
dna
polym
may
affect
nucleic
acid
persist
dearth
inform
persist
virusvector
vaccin
recombin
mva
outsid
host
although
persist
differ
materi
wildtyp
virus
commonli
employ
vector
avail
thu
often
assum
persist
gm
virusesvector
differ
wildtyp
strain
ignor
fact
genet
manipul
may
affect
biolog
properti
gm
virusvector
result
persist
differ
correspond
parent
viru
exampl
insert
sequenc
influenc
genom
stabil
viral
vector
result
improperli
packag
enlarg
unstabl
genom
prone
rearrang
transmiss
nontarget
host
person
consid
risk
exposur
viru
vectorvirusvector
vaccin
come
close
contact
vaccine
often
famili
member
health
care
worker
well
pet
anim
close
contact
vaccine
knowledg
biodistribut
shed
immunolog
statu
vaccine
close
contact
help
identifi
rout
transmiss
virusvector
inadvert
transmit
individu
clearanc
effect
given
good
proport
popul
alreadi
preexist
immun
vacvmva
howev
close
contact
compromis
immun
due
old
age
young
sick
immunosuppress
drug
clearanc
may
ineffici
consequ
infect
might
signific
individu
interact
exchang
genet
materi
helper
function
gene
productsfactor
gm
viru
vector
resid
natur
virus
could
gener
quasi
viru
speci
unstabl
constantli
mutat
could
lead
speci
alter
epitop
thu
less
infect
alter
epitop
result
less
effici
immun
clearanc
due
weak
bind
receptor
immun
cell
lead
establish
chronic
latent
persist
infect
situat
nonneutr
antibodi
facilit
infect
cell
antibodydepend
enhanc
infect
may
aris
respect
mvamvavector
vaccin
potenti
transmiss
nontarget
host
low
due
multipl
incompet
mammalian
cell
howev
observ
demonstr
vitro
relev
cell
cultur
well
immunecompet
immunedefici
anim
mvavector
vaccin
confirm
multipl
compet
restor
recombin
mva
vaccin
mva
consid
safe
vaccin
smallpox
howev
anim
studi
show
higher
multipl
dose
boost
requir
obtain
antivacv
antibodi
respons
obtain
singl
dose
wildtyp
vacv
thu
mva
higher
immunogen
recombin
mva
vector
elicit
improv
immun
respons
heterolog
antigen
still
reduc
virul
need
vacv
encod
sever
protein
involv
evas
host
immun
respons
mva
lack
sever
gene
increas
immunogen
viru
vacv
infect
mice
human
induc
humor
antibodi
secret
b
cell
plasma
cell
cellmedi
cell
respons
vacv
use
vaccin
vector
highli
attenu
strain
mva
develop
mva
retain
immun
stimulatori
properti
see
recent
review
administr
mva
anim
model
lead
induct
type
type
ii
interferon
ifn
proinflammatori
cytokin
chemokin
critic
mediat
host
antivir
respons
addit
virusspecif
cell
respons
develop
includ
memori
cell
respons
despit
mutat
major
delet
mva
genom
still
encod
sever
protein
immunomodulatori
function
delet
gene
encod
immunomodul
increas
immun
respons
vacv
demonstr
gene
singl
remov
gene
result
increas
viralspecif
cell
respons
enhanc
protect
challeng
virul
vacv
wr
mice
increas
immun
respons
also
measur
infect
mva
lack
studi
suggest
mva
depriv
addit
immunomodulatori
gene
may
repres
improv
vaccin
vector
effect
delet
mva
gene
mvabas
vector
express
foreign
antigen
immun
respons
antigen
also
examin
delet
singl
multipl
mva
immunomodulatori
gene
stimul
immun
respons
foreign
protein
express
recombin
mva
mutant
altern
recombin
mva
vector
express
host
gene
encod
immun
stimul
protein
may
trigger
increas
immun
respons
shown
mva
express
granulocytemacrophag
colonystimul
growth
factor
gmcsf
cc
motif
chemokin
ligand
mice
howev
rhesu
macaqu
high
dose
gmcsf
express
mvagmcsf
inhibit
mucos
antibodi
respons
diminish
protect
elicit
mvasimian
immunodefici
viru
siv
macaqu
vaccin
reintroduc
vacv
gene
mva
modifi
immun
respons
mva
warrant
caution
illustr
studi
back
cowork
found
mva
lack
gene
could
prevent
phosphoryl
event
import
antivir
respons
mediat
interferon
reinsert
gene
involv
inhibit
absent
mva
restor
phosphoryl
indic
complementari
function
protein
immunogen
mva
alter
delet
immunomodulatori
gene
also
posttransl
modif
viral
structur
protein
roja
colleagu
found
glycosyl
state
vacv
particl
impact
immun
respons
vacv
natur
activ
tolllik
receptor
associ
induct
antivir
neutral
antibodi
respons
deglycosyl
viru
particl
block
activ
greatli
reduc
product
antivir
antibodi
affect
infect
glycosyl
mva
use
increas
immun
respons
caus
better
protect
poxviru
infect
vaccin
vacv
strain
multipli
patient
glycosyl
defect
may
result
poorer
immun
respons
poorer
protect
poxviru
infect
strategi
use
improv
immunogen
recombin
mva
besid
delet
immunomodulatori
gene
includ
immun
primeboost
virus
dna
vector
insert
gene
encod
costimulatori
molecul
eg
interleukin
increas
express
foreign
antigen
eg
promot
strength
codon
optim
termin
signal
peptid
adjuv
eg
glucopyranosyl
lipid
review
thu
modul
express
mva
gene
manner
improv
immunogen
mva
vaccin
activ
immun
respons
heterolog
antigen
howev
effect
strategi
biosafeti
mva
includ
attenu
multipl
incompet
cell
tissu
tropism
genom
stabil
biodistribut
shed
mostli
investig
cytokin
profil
character
interleukin
il
product
typic
respons
infectionimmun
mva
recombin
mva
provok
respons
delet
mva
gene
increas
respons
exampl
level
cytokin
significantli
higher
mice
inocul
anim
challeng
mva
higher
frequenc
ifn
secret
tcell
observ
week
vaccin
mva
lack
compar
mva
mvac
mva
vector
express
envelop
protein
gagpolnef
subtyp
c
induc
produc
cell
number
cell
higher
upon
infect
mutant
lack
gene
gene
encod
costimulatori
molecul
cytokin
insert
mva
vector
order
improv
immunogen
evid
provid
show
molecul
predominantli
result
respons
multipl
compet
opv
vector
insert
result
increas
pathogen
recombin
viru
due
inhibit
respons
present
provis
cytokin
profil
data
obligatori
era
mva
mvavector
vaccin
howev
provis
data
import
evalu
risk
potenti
revers
mva
vector
wild
type
mva
depend
host
pathway
success
gener
progeni
must
also
counteract
inflammatori
innat
acquir
immun
respons
pathway
prevent
viral
replic
vacv
infect
result
activ
akt
signal
pathway
one
akt
substrat
human
cyclic
guanosin
monophosphateadenosin
monophosph
synthetas
cga
phosphoryl
cga
inhibit
product
type
ifn
inflammatori
cytokin
therebi
prevent
antivir
respons
henc
vacv
trigger
akt
activ
help
viru
evad
host
defens
mechan
known
whether
mva
infect
lead
akt
activ
anoth
pathway
modul
upon
mva
infect
mitogenactiv
protein
kinas
mapk
pathway
gedey
colleagu
found
mva
activ
cell
contrast
find
schwenek
et
al
show
cva
induc
sustain
erk
activ
cell
mva
fail
author
demonstr
activ
depend
intact
gene
gene
fragment
mva
use
differ
cell
line
may
explain
discrep
find
studi
infect
hela
cell
mous
embryon
fibroblast
mef
mva
result
upregul
dual
specif
phosphatas
mapk
dephosphoryl
enzym
infect
knockout
mice
mva
enhanc
product
proinflammatori
cytokin
indic
involv
regul
innat
adapt
immun
respons
poxviru
infect
vacv
activ
mapk
cjun
ntermin
protein
kinas
whether
mva
activ
jnk
mapk
pathway
investig
inhibit
pathway
caus
signific
declin
viru
yield
cell
knowledg
alway
accompani
uncertainti
uncertainti
respect
risk
character
refer
lack
incomplet
knowledg
likelihood
advers
effect
occur
ii
lack
insuffici
knowledg
magnitud
consequ
advers
effect
occur
shown
section
insuffici
knowledg
data
aspect
mva
biolog
relev
hazard
character
thu
least
epistem
uncertainti
although
direct
supplementari
commiss
decis
recommend
identifi
uncertainti
analyz
era
gmo
medicin
product
contain
gmo
era
mvavector
vaccin
peerreview
literatur
publicli
avail
dossier
submit
ema
incorpor
methodolog
identif
uncertainti
uncertainti
analysi
contrari
knowledg
characterist
mva
vector
relev
era
present
determin
impli
uncertainti
low
neglig
believ
simplif
neither
serv
scientif
commun
research
progress
field
risk
crisi
commun
consid
best
practic
emphas
acknowledg
uncertainti
hazard
character
mvavector
vaccin
futur
character
natur
locat
level
identifi
uncertainti
employ
uncertainti
analysi
uncertainti
analysi
use
differ
typolog
alreadi
develop
genet
modifi
gm
plant
chemic
pollut
nanoparticl
could
adapt
appli
era
virusvector
vaccin
includ
recombin
mva
vaccin
worstcas
assumpt
test
eventu
reject
proven
essenti
substep
risk
character
gmo
includ
genet
modifi
virus
plant
step
use
era
gmv
outlin
section
probabilist
distribut
frequenc
advers
effect
level
consequ
associ
advers
effect
rather
rate
risk
neglig
low
moder
high
larg
base
weight
evid
woe
peerreview
literatur
expert
opinion
scientist
commiss
regulatori
agenc
like
ema
much
publish
literatur
mvavector
vaccin
address
vaccin
efficaci
rather
aspect
relev
era
test
worstcas
scenario
falsifi
reduc
uncertainti
sinc
risk
analysi
worstcas
scenario
shown
occur
evid
risk
advers
effect
low
case
mvavector
vaccin
assumpt
worstcas
scenario
recombin
wildtyp
opv
emerg
virul
hybrid
progeni
falsifi
reject
experiment
investig
authent
immunocompromis
immunocompet
anim
model
paper
highlight
knowledg
gap
pauciti
scientif
data
key
aspect
mva
biolog
requir
hazard
character
present
data
obtain
vitro
worstcas
scenario
demonstr
mva
product
infect
human
cell
multipl
serial
passag
cell
ii
recombin
vitro
mva
vector
vaccin
wild
type
cpxv
cell
line
semipermiss
mva
provis
empir
data
fill
gap
knowledg
improv
hazard
character
mvavector
vaccin
result
robust
era
